Colorectal Cancer

On August 2, 2023, the FDA approved a new indication for trifluridine and tipiracil (Lonsurf; Taiho Oncology), in combination with bevacizumab (Avastin), for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; an anti–vascular endothelial growth factor biologic therapy; and if RAS wild-type, an anti–epidermal growth factor receptor therapy.
Read Article

A new report released by the American Cancer Society (ACS) shows that the incidence of colorectal cancer is rapidly increasing among younger individuals, and the disease is also being diagnosed at more advanced stages in people of all ages.
Read Article

On January 19, 2023, the FDA accelerated the approval of tucatinib (Tukysa; Seagen), a Bruton tyrosine kinase inhibitor, in combination with trastuzumab (Herceptin), a HER2/neu receptor agonist, for the treatment of RAS wild-type, HER2-positive, unresectable or metastatic colorectal cancer (CRC) that progressed after fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies.
Read Article

Adagrasib (MRTX849), an inhibitor of the KRASG12C mutation, showed promising activity as monotherapy and in combination with cetuximab (Erbitux) in patients with metastatic colorectal cancer (CRC) in the phase 1/2 KRYSTAL-1 trial.
Read Article

Chemotherapy is currently the standard of care for patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer (CRC); however, some patients have disease that is refractory to chemotherapy.
Read Article

San Francisco, CA—The combination of encorafenib (Braftovi) plus cetuximab (Erbitux), with or without binimetinib (Mektovi), improved the quality of life based on patient-reported assessments better than current standard of care in the treatment of patients with metastatic colorectal cancer (CRC) and BRAF V600E mutation, according to the BEACON CRC study, which was presented at the 2020 Gastrointestinal Cancers Symposium.

Read Article

San Francisco, CA—The immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy) provides durable clinical benefit in patients with previously treated DNA mismatch repair–deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (CRC).
Read Article



New recommendations issued by the US Preventive Services Task Force (USPSTF) focus on increasing colorectal cancer screening, which, according to the task force, is “a substantially underused preventive health strategy.” Previous USPSTF guidelines recommended specific screening approaches, including colonoscopy, fecal occult blood testing, or sigmoidoscopy, for adults aged 50 through 75 years.
Read Article

Page 1 of 2